Latest news with #OTI
New Paper
03-05-2025
- Sport
- New Paper
All stoked up with Femminile
Femminile became the second filly in a row to claim the South Australian Derby at Morphettville (2,500m) on May 3. Last year, it was second favourite Coco Sun who delivered the A$1 million (S$836,000) Group 1 event for trainers Tony and Calvin McEvoy's and jockey Jamie Melham's (then Kah) first success in the Adelaide classic. Similarly, Femminile allowed both trainer Philip Stokes and jockey Lachlan Neindorf to enter their home Derby honour roll for the first time, except that the Dundeel three-year-old was a lot less fancied at $103 on the Singapore tote. But from the halfway mark, she was travelling a lot more like a $10 favourite as she crept up along the rails for LachlanNeindorf, taking all the shortcuts home. She did not go around any runners as she went for broke upon straightening, collaring race-leader Goldrush Guru (Jason Holder) from underneath him before setting sail for home. Femminile may have hit the front too soon, but even if the last 300m of the home straight must have felt endless to connections, she kept hitting the line strongly. Favourite Statuario (John Allen) rushed home late but had to settle for second place 3/4-length away with second favourite Lavalier completing the trifecta another 1 3/4 lengths away, failing to give Melham back-to-back Derby wins. On the other hand, OTI Racing has gone one better after Warmonger could come only within 1½ lengths of Coco Sun last year. "We're just so proud. This horse has been prepped up an absolute treat," said Stokes' assistant-trainer son Tommy. "Full credit to the team at Pakenham and Morphettville. It's a big operation, the team, mum and dad put in a lot of work. "She's just been prepped up a tee. The back-up really suited, stepping up in trip. We were doing a bit of a rain dance before today but she didn't need it. "Lachie gave her an absolute peach. It was quite an effortless watch in the end. "It's another Group 1 winner for OTI. Can't wait to celebrate, it's a shame dad's (at Caulfield) not here, but I'm sure he's super proud. "So rapt for Lachie. He does a fair bit of work on this filly, but that was his first race ride on her." Neindorf, 22, was at his second Group 1 win after breaking his duck at the elite level with another Stokes ward, Climbing Star in the Robert Sangster Stakes (1,200m) a year ago on April 27, 2024. While Neindorf could not control the waterworks at that milestone, he was a lot more composed this time, but just as overjoyed. "It's funny. About a month after (the Robert Sangster), I went to Flemington, rode one for Phil and the team," said Neindorf. "Think it was Pat Carey next to Phil, he said 'gee, you must've taught that boy everything', Phil said 'I didn't teach him how to bloody cry'. "So, from that day on, you know what, I'm not crying again. No more tears." The 10-out-of-10 handling from barrier No. 2 itself was the epitome of coolness. "I just said to the boys pre-race, let's just lob out and keep her happy. I think these distance races, you see a lot of these top-class jockeys, they just worry about the race from the 1,200m onwards," he said. "Before that, it's just about getting the horse to relax and get the rhythm in. It was a bit messy, a few horses got pulling, but she just copped it all. "I was on the back of John Allen and trusted he would take me around and (I was) ready to go. "He popped off the fence and I lost his back. I thought, let's make it up as we go, the seas just parted." manyan@
Yahoo
10-04-2025
- Business
- Yahoo
Premier Biotech Increases Offerings and Global Distribution Network with Recent Acquisitions
CLEVELAND & DALLAS, April 10, 2025--(BUSINESS WIRE)--Align Capital Partners' ("ACP") toxicology testing solutions provider Premier Biotech ("Premier" or the "Company") completed two successive acquisitions including OraSure Technologies, Inc.'s ("OTI") substance abuse testing business line (the "OraSure Toxicology Line"), and separately, the Mexican subsidiary of Green Earth Biomedical LLC ("GEM"), an international provider of drug testing solutions. In November 2024, OTI announced that it was exiting the substance abuse testing business. In connection with that decision, on March 27, 2025, Premier acquired certain assets of OTI that make up the OraSure Toxicology Line, but not including the OraSure name or trademark. Prior to its exit, OTI was a global leader in oral fluid substance abuse testing products serving the employment, forensic and substance abuse treatment markets. The OraSure Toxicology Lines' unique assays provide accurate and easy-to-administer testing methods to help determine the presence, or absence, of drugs or alcohol in a person's system. Oral fluid-based testing products provide a simplified collection process, faster results and cost savings, with minimal risk of tampering and dramatically reduced risk of adulteration. The OraSure Toxicology Line acquisition further solidifies Premier's oral fluid leadership position in toxicology diagnostics and services; plus, expands Premier's service offering and customer relationships. "OTI's substance abuse testing products are known for their quality, innovation, and most importantly, ease of use. While broadening Premier's offerings, this acquisition reflects the Company's unwavering commitment to expand the oral fluid market as a whole and enhance Premier's oral fluid leadership position within the toxicology space. As the market continues to transition to oral fluid, we are building a complete set of diagnostic solutions and are thrilled to offer additional lab based oral fluid choices to the market," said Premier CEO Matt Michalik. GEM is a domestic and international distributor of drug testing solutions and Premier's current international distributor in Mexico and Latin America. GEM is a very strategic acquisition that will allow Premier to accelerate its international expansion and serve the needs of customers in very challenging and complex markets. Premier Biotech has completed three acquisitions since partnering with ACP in November of 2022. The Company will continue to pursue additional acquisitions and collaboration opportunities to further accelerate its growth. ACP Managing Partner Rob Langley, Operating Partner Ervin Cash, Principal Matt Bowen and Associate Sarah Mahosky worked alongside Premier Management on the transaction. About Premier Biotech Premier Biotech delivers rapid and innovative diagnostic solutions that promote health, safety and compliance. The Company is a leading provider of proprietary oral fluid (OralTox® and OT-Scan®) and other products, services and technology solutions are designed to simplify and provide a seamless end-to-end experience for customers. Premier differentiates itself through its fully integrated service offering that is augmented with high levels of service, technical expertise and customization. The Company's integrated offering is utilized in workplace (pre-employment, post-employment and DOT), government (child and family services, probation, parole, corrections and law enforcement) and healthcare settings. For more information, visit About Align Capital Partners Align Capital Partners is a growth-oriented private equity firm that partners with business owners and management teams to help create shared success. ACP manages $1.8 billion in committed capital with investment teams in Cleveland and Dallas. ACP brings experience and resources to help lower-middle market companies accelerate their growth, to the benefit of management, employees, and the firm's investors. ACP makes control investments in differentiated companies within the business services, technology, specialty manufacturing and distribution sectors. For more information, visit View source version on Contacts Media Inquiries Katie Noggle216-505-6463knoggle@ Sign in to access your portfolio
